"Everyone deserves to have a bowl of ice cream before bed every night."
Michael Step, CEO of Ritter Pharmaceuticals Inc., discussing initiation of the phase IIb/III study of the RP-G28, the company's candidate to treat lactose intolerance

"We really like to align very closely with world-class academic founders, who have been working on something their whole life and now is the time to move it into an applied setting. That fit the Sunrise model."
Kathy Bowdish, vice president of global R&D and head of the Sanofi Sunrise Initiative, discussing the potential $2.26 billion deal with start-up Dice Molecules SV LLC leveraging the use of directed evolution in chemistry

"With small molecules, we believe that it will be possible to transform cancer immunotherapy from a phenotypic approach to a genotypic approach. There is still a lot of work to be done and a lot of new opportunities to further increase the immune response, to broaden the utility of these approaches and to treat additional cancer types."
Christoph Lengauer, chief scientific officer, Blueprint Medicines Corp., which signed a potential $1 billion deal with Roche AG units F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. covering the development of up to five small molecule drugs targeting kinases deemed important in cancer immunotherapy

"This is fundamental to gene expression and varies by tissue types. Ultimately, we see it as being just as – if not more – important than genomics. Unless there is a SNP [single nucleotide polymorphism] or a point mutation, genomes don't change. The epigenome does, and it is different in different cells."
Theo Patsalos-Fox, head of strategy, Cambridge Epigenetix Ltd., whose company raised raised $21 million in a series B round to advance its epigenome sequencing technology